| __timestamp | BioMarin Pharmaceutical Inc. | Exelixis, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 461543000 | 189101000 |
| Thursday, January 1, 2015 | 634806000 | 96351000 |
| Friday, January 1, 2016 | 661905000 | 95967000 |
| Sunday, January 1, 2017 | 610753000 | 112171000 |
| Monday, January 1, 2018 | 696328000 | 182257000 |
| Tuesday, January 1, 2019 | 715007000 | 336964000 |
| Wednesday, January 1, 2020 | 628116000 | 547851000 |
| Friday, January 1, 2021 | 628793000 | 693716000 |
| Saturday, January 1, 2022 | 649606000 | 891813000 |
| Sunday, January 1, 2023 | 746773000 | 1044071000 |
| Monday, January 1, 2024 | 747184000 | 910408000 |
Unveiling the hidden dimensions of data
In the competitive world of biotechnology, innovation is the lifeblood of success. Over the past decade, BioMarin Pharmaceutical Inc. and Exelixis, Inc. have demonstrated a steadfast commitment to research and development (R&D), as evidenced by their annual spending trends.
BioMarin has consistently invested in R&D, with expenditures growing by approximately 62% from 2014 to 2023. This commitment underscores their dedication to pioneering treatments for rare genetic diseases. Meanwhile, Exelixis has shown an even more dramatic increase, with R&D spending surging by over 450% during the same period, reflecting their aggressive pursuit of cancer therapies.
By 2023, Exelixis outpaced BioMarin, spending 40% more on R&D. This shift highlights Exelixis's strategic focus on expanding its oncology pipeline. As these companies continue to innovate, their R&D investments will likely shape the future of biotech breakthroughs.
BioMarin Pharmaceutical Inc. vs Exelixis, Inc.: Efficiency in Cost of Revenue Explored
R&D Spending Showdown: BioMarin Pharmaceutical Inc. vs Ultragenyx Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. vs ADMA Biologics, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for BioMarin Pharmaceutical Inc. and Amneal Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: BioMarin Pharmaceutical Inc. vs Amicus Therapeutics, Inc.
Comparing Innovation Spending: BioMarin Pharmaceutical Inc. and Soleno Therapeutics, Inc.
Research and Development Expenses Breakdown: BioMarin Pharmaceutical Inc. vs Galapagos NV
R&D Insights: How Exelixis, Inc. and CymaBay Therapeutics, Inc. Allocate Funds
Exelixis, Inc. or Corcept Therapeutics Incorporated: Who Invests More in Innovation?
Research and Development: Comparing Key Metrics for Exelixis, Inc. and Ionis Pharmaceuticals, Inc.
Research and Development Investment: Exelixis, Inc. vs Alkermes plc
R&D Insights: How Exelixis, Inc. and Amicus Therapeutics, Inc. Allocate Funds